SCHEDULE 13G/A: Acorn Bioventures and Affiliates Disclose Significant Passive Stake in BioAtla, Inc.

Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., and their affiliates, including Anders Hove, have disclosed a combined beneficial ownership of 8.3% of BioAtla, Inc.'s common stock as a passive investment.

Summary

• This Schedule 13G/A filing (Amendment No. 4) reports the beneficial ownership of common stock in BioAtla, Inc. by Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., Acorn Capital Advisors GP, LLC, Acorn Capital Advisors GP 2, LLC, and Anders Hove.
• Anders Hove, as the manager of the general partners for both Acorn Bioventures funds, is deemed to beneficially own a total of 4,835,111 shares of BioAtla, Inc. common stock.
• This aggregate ownership represents 8.3% of BioAtla, Inc.'s outstanding common stock.
• The percentage of class is calculated based on 58,418,142 shares of common stock outstanding as of May 2, 2025, as reported in BioAtla's most recent 10-Q filing.
• Acorn Bioventures, L.P. beneficially owns 2,162,205 shares, representing 3.7% of the class.
• Acorn Bioventures 2, L.P. beneficially owns 2,672,906 shares, representing 4.6% of the class.
• The filing indicates that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, consistent with a passive investment strategy.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual disclosure, the presence of a significant institutional investor like Acorn Bioventures, particularly with a passive intent, can be viewed favorably by the market as a vote of confidence in the company's value proposition.

Positives

• The disclosure of a significant beneficial ownership stake by institutional investors like Acorn Bioventures can signal confidence in BioAtla, Inc.'s long-term prospects.
• The passive nature of the investment, as stated in the filing, suggests that the investors are not seeking to disrupt company operations or management.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding BioAtla, Inc.'s future performance or strategic direction. It solely reports beneficial ownership.

Industry Context

Institutional investment in biotechnology companies like BioAtla, Inc. is common, reflecting investor interest in the sector's growth potential and specific therapeutic pipelines. A significant passive stake by a specialized bioventures fund indicates a long-term investment perspective in the company's drug development or commercialization efforts.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and potentially attract new investors, as it signals a professional assessment of the company's value.

Key Dates

Keywords

BioAtla Inc., Common Stock, Schedule 13G, Beneficial Ownership, Institutional Investor, Acorn Bioventures, Passive Investment, SEC Filing